BUZZ-Mizuho raises CVS Health's PT on its business diversification

Reuters

14 Mar

BUZZ-Mizuho raises CVS Health's PT on its business diversification

** Brokerage Mizuho raises healthcare conglomerate CVS Health's CVS.N PT to $70 from $58, with "outperform" rating

** New PT represents ~14% upside to the stock's close

** Brokerage says CVS is "an attractive investment opportunity given the diversification of its business"

** "We believe CVS' long-term adjusted EPS growth floor is predicated on market share gains and the success of the company's new cost-plus pharmacy reimbursement model" - brokerage adds

** Eighteen of 29 brokerages rate the stock "buy" or higher, eleven "hold"; their median PT is $70.89 - data compiled by LSEG

** CVS has fallen 12.4% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2519338866"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519338866\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2519338866?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-14 22:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2519338866","market":"nz","top_or_hot":-1,"title":"BUZZ-Mizuho raises CVS Health's PT on its business diversification","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Mizuho raises CVS Health's PT on its business diversification</title></head><body><p>** Brokerage Mizuho raises healthcare conglomerate CVS Health's <span>CVS.N</span> PT to $70 from $58, with \"outperform\" rating </p><p>** New PT represents ~14% upside to the stock's close</p><p>** Brokerage says CVS is \"an attractive investment opportunity given the diversification of its business\"</p><p>** \"We believe CVS' long-term adjusted EPS growth floor is predicated on market share gains and the success of the company's new cost-plus pharmacy reimbursement model\" - brokerage adds</p><p>** Eighteen of 29 brokerages rate the stock \"buy\" or higher, eleven \"hold\"; their median PT is $70.89 - data compiled by LSEG</p><p>** CVS has fallen 12.4% in the past 12 months</p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Mizuho raises CVS Health's PT on its business diversification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Mizuho raises CVS Health's PT on its business diversification\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-14 22:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Mizuho raises CVS Health's PT on its business diversification</title></head><body><p>** Brokerage Mizuho raises healthcare conglomerate CVS Health's <span>CVS.N</span> PT to $70 from $58, with \"outperform\" rating </p><p>** New PT represents ~14% upside to the stock's close</p><p>** Brokerage says CVS is \"an attractive investment opportunity given the diversification of its business\"</p><p>** \"We believe CVS' long-term adjusted EPS growth floor is predicated on market share gains and the success of the company's new cost-plus pharmacy reimbursement model\" - brokerage adds</p><p>** Eighteen of 29 brokerages rate the stock \"buy\" or higher, eleven \"hold\"; their median PT is $70.89 - data compiled by LSEG</p><p>** CVS has fallen 12.4% in the past 12 months</p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL4N3PX0X3:1","article_id":"2519338866","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519338866","pubTimestamp":1741961907,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Mizuho raises CVS Health's PT on its business diversification** Brokerage Mizuho raises healthcare conglomerate CVS Health's CVS.N PT to $70 from $58, with \"outperform\" rating ** New PT represents ~14% upside to the stock's close** Brokerage says CVS is \"an attractive investment opportunity given the diversification of its business\"** \"We believe CVS' long-term adjusted EPS growth floor is predicated on market share gains and the success of the company's new cost-plus pharmacy reimbursement model\" - brokerage adds** Eighteen of 29 brokerages rate the stock \"buy\" or higher, eleven \"hold\"; their median PT is $70.89 - data compiled by LSEG** CVS has fallen 12.4% in the past 12 months  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"BUZZ-Mizuho提高CVS Health业务多元化的PT","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":0.9},"content_text":"BUZZ-Mizuho raises CVS Health's PT on its business diversification** Brokerage Mizuho raises healthcare conglomerate CVS Health's CVS.N PT to $70 from $58, with \"outperform\" rating ** New PT represents ~14% upside to the stock's close** Brokerage says CVS is \"an attractive investment opportunity given the diversification of its business\"** \"We believe CVS' long-term adjusted EPS growth floor is predicated on market share gains and the success of the company's new cost-plus pharmacy reimbursement model\" - brokerage adds** Eighteen of 29 brokerages rate the stock \"buy\" or higher, eleven \"hold\"; their median PT is $70.89 - data compiled by LSEG** CVS has fallen 12.4% in the past 12 months (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}